iPath Series B Bloomberg Cotton Subindex Total Return ETN
Limited financial coverage for BAL.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
Price Chart
About the company
This Exchange Traded Note (ETN) provides investors with exposure to commodity markets by tracking futures contracts, rather than offering direct ownership of the physical goods themselves. The benchmark index that this ETN aims to replicate is composed of one or more futures agreements on the designated commodity. Its objective is to mirror the potential returns generated from two sources: firstly, a straightforward, unleveraged investment in those specific futures contracts, and secondly, the interest income that could be accrued from cash collateral placed in particular Treasury Bills.
- IPO
- 2018
- HQ
- New York, NY, US
Get TickerSpark's AI analysis on BAL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- 52W High
- $63.52
- 52W Low
- $54.51
- 50D MA
- $60.90
- 200D MA
- $59.46
- Beta
- 1.17
- RSI (14)
- 54
- Avg Volume
- 0
No earnings-call transcripts are available for BAL yet.
- Free Float
- 0.0%
- Shares Outstanding
- 78.56K
- Float Shares
- 0
of shares held by institutions
10 13F filers
Our BAL coverage
Recent articles, reports, and earnings notes.
No research on BAL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BAL report →Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
gurufocus.com · Oct 3
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026
gurufocus.com · Oct 2
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL's Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
gurufocus.com · Aug 28
Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer
gurufocus.com · Aug 26
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026
gurufocus.com · Jun 25
Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420
globenewswire.com · Apr 9
Basilea announces start of first‑in‑human study of novel antibiotic BAL2420
globenewswire.com · Mar 23
Basilea receives USD 25 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062
globenewswire.com · Sep 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.